Related Experiment Video

Updated: May 1, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.2K

Editorial Comment to Real-World Effectiveness and Safety of Pembrolizumab-Lenvatinib Versus Axitinib-Based Regimens

Tsunenori Kondo1

  • 1Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.

International Journal of Urology : Official Journal of the Japanese Urological Association
|April 30, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Renal cell carcinomakidney function testsnephrectomyorgan sparing treatmentpostoperative complications

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.0K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.2K

Related Experiment Videos

Last Updated: May 1, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.2K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.0K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

Articles linked to this work by shared authors, journal, and citation graph.

Factors Associated With Trifecta and Pentafecta Achievement in Robot-Assisted Laparoscopic Partial Nephrectomy for Highly Complex Renal Tumors.

International journal of urology : official journal of the Japanese Urological Association·2026

Prognostic impact of lenvatinib dose intensity in previously untreated patients with advanced renal cell carcinoma receiving lenvatinib plus pembrolizumab.

Japanese journal of clinical oncology·2026

Standardizing Upper Abdominal Fascial Terminology: A Transdisciplinary Expert Consensus From the Japanese Society for Endoscopic Surgery.

Asian journal of endoscopic surgery·2026

Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.

International urology and nephrology·2026

Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.

Japanese journal of clinical oncology·2026

Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors.

Molecular cancer research : MCR·2026

Real-World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma.

International journal of urology : official journal of the Japanese Urological Association·2026

Low Frequency of Sexual Intercourse, Discrepancy Between Erectile Function Measures, and Sexual Satisfaction Among Japanese Men Aged 45-64 Years: A Nationwide Cross-Sectional Study.

International journal of urology : official journal of the Japanese Urological Association·2026

Interpreting International Real-World Survival Outcomes After Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma: An RMST Analysis of Reconstructed Individual Patient Data.

International journal of urology : official journal of the Japanese Urological Association·2026

Maternal Parenting Styles and Nighttime Diaper Use in Early Childhood: The Japan Environment and Children's Study.

International journal of urology : official journal of the Japanese Urological Association·2026

Changes in Treatment Patterns and Survival Outcomes Across Therapeutic Eras in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study.

International journal of urology : official journal of the Japanese Urological Association·2026

Intraoperative Ultrasound Guided Sling Adjustment During Transobturator Sling Placement: A Preliminary Pilot Report of the Technical Protocol and Feasibility.

International journal of urology : official journal of the Japanese Urological Association·2026

Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".

Current oncology (Toronto, Ont.)·2026

Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.

Current oncology (Toronto, Ont.)·2026

Electroacupuncture Combined with Cognitive Behavioral Therapy for Insomnia Alleviates Insomnia-Anxiety Comorbidity in Gynecological Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial.

Current oncology (Toronto, Ont.)·2026

[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.

Current oncology (Toronto, Ont.)·2026

A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.

Current oncology (Toronto, Ont.)·2026

A Remotely Delivered Exercise-Based Rehabilitation Program for Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy (EX-CIPN): A Phase I Feasibility Trial.

Current oncology (Toronto, Ont.)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us